Lipodystrophy can be avoided by selecting therapies with benign effects on adipose tissue.
Switching from certain HIV protease inhibitors may normalize the metabolic profile fairly …

HIV-associated lipodystrophy is a term used to describe a constellation of body composition
(lipoatrophy and lipohypertrophy) and metabolic (dyslipidemia and insulin resistance) …

Objective: Lipodystrophy in HIV-1–infected antiretroviral-treated patients is often associated
with opposite alterations in adipose tissue depots as follows: lipoatrophy of subcutaneous …

Accumulation of dorsocervical fat, or a “buffalo hump”(BH), is commonly reported in adults
with HIV-associated lipodystrophy (HIVLD). The pathogenesis underlying this aspect of a …

AIDS: Lipodystrophy is defined as the defective metabolism of fat, and it is characterized by
distinct physical changes, such as an increased waist size or an accumulation of fatty tissue …

A 35-year-old man as diagnosed with HIV infection in 1989. He was treated initially with
zidovudine monotherapy, then zidovudine, lamivudine and saquinavir in 1996, with the …

Early in the HIV epidemic, lipodystrophy, characterized by subcutaneous fat loss
(lipoatrophy), with or without central fat accumulation (lipohypertrophy), was recognized as a …

Background Fat abnormalities are common among HIV-infected persons, but few studies
have compared regional body fat distribution, including visceral fat, in HIV-infected and HIV …

Materials and Methods The “Groupe Lipo & Metabolism” is a multidisciplinary consultation
where patients undergo a standard evaluation including questionnaire, physical …

Objective To estimate the incidence of lipoatrophy and lipohypertrophy among HIV-infected
and HIV-uninfected women from the Women's Interagency HIV Study. Design Eight hundred …